DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Venous Thromboembolism Therapeutics Market 2017-2021" report to their offering.
The global venous thromboembolism therapeutic market to grow at a CAGR of 6.40% during the period 2017-2021.
The global VTE therapeutics market is expected to benefit from the growing incidence of VTE worldwide. According to the CDC, every year around 0.9 million individuals are affected by VTE in the US and 60,000 to 100,000 individuals in the US die of VTE. Further, the presence of high unmet medical needs is expected to fuel the market growth. For instance, according to the CDC approximately 50% of individuals with VTE will have long-term complications, and 33% of individuals will have a recurrence within ten years.
The report, Global Venous Thromboembolism Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.
Key vendors:
- Bayer HealthCare
- BMS
- Boehringer Ingelheim
- Daiichi Sankyo
- Johnson & Johnson
- Sanofi
Other Prominent Vendors:
- Altor Bioscience
- Armetheon
- Aspen Pharma
- BioInvent International
- eXIthera Pharmaceuticals
- Gamma Therapeutics
-
Others
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by drug class
PART 09: Geographical segmentation
PART 10: Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
PART 16: Key vendor analysis
PART 17: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/ctr67p/global_venous
